Company: SNWV
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023881
Chunk: 70

Company: SANUWAVE Health, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 8
Chunk 70
---
 by dividing the net loss attributable to common stockholders by the weighted average number of shares outstanding for the three months ended March 31, 2025, and 2024. The weighted average number of shares outstanding includes outstanding common stock and shares issuable for nominal consideration. Accordingly, warrants issued with a $0.01 per share exercise price, are included in weighted average shares outstanding as follows:Three Months Ended(in thousands)March 31, 2025March 31, 2024Weighted average shares outstandingCommon shares8,548 3,041 Common shares issuable assuming exercise of nominally priced warrants- 58 Weighted average shares outstanding8,548 3,099 Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding. To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net loss per share. As a result of the net loss for each of the three months ended March 31, 2025, and March 31, 2024, all potentially dilutive shares in such periods were anti-dilutive and therefore excluded from the computation of diluted net loss per share.Three Months Ended(in thousands)March 31, 2025March 31, 2024Common stock options1,233 43 Common stock purchase warrants390 3,807 Convertible notes payable, including interest- 758 1,623 4,608 

15.        Concentration of Credit Risk and Limited Suppliers 

The Company currently purchases most of its product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in the Company’s production. The percentage of purchases from major vendors 

18

of the Company that exceeded ten percent of total purchases for the three months ended March 31, 2025, and 2024 were as follows:Three Months EndedMarch 31, 2025March 31, 2024Purchases:Vendor A25 %- %Vendor B13 %- %

16.        License and Option Agreement

In March 2024, the Company entered into an exclusive license and option agreement (the "Patent License") with a third party licensee in connection with a portfolio of patents related to the field of intravascular shockwave applications. The Company received a one-time payment of $2.5 million related to